Healthcare / Drug Manufacturers - Specialty & GenericBSE
$179.15
-8.65 (-4.61%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 35% · confianza 11%
FCF escenarios
weak_data · normalized FCF $-58.7M · quality 24.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
8/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.3B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-148.9%
↓Gross Margin
79.0%
↑Debt/Equity
7.77
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+12.1%
FCF CAGR
—
FCF margin
-22.7%
FCF / Net income
1.80x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.31B · net income $-165.6M · FCF $-297.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.31B | $1.31B | $1.20B | $1.03B | $930.5M |
| Net Income | $-165.6M | $-165.6M | $-147.0M | $-5.6M | $-9.0M |
| EBITDA | $-35.4M | $-35.4M | $-31.7M | $74.5M | $53.7M |
| EPS | — | — | -12.79 | -0.51 | -0.85 |
| Gross Margin | 79.0% | 79.0% | 81.1% | 75.5% | 75.5% |
| Operating Margin | -17.7% | -17.7% | -8.3% | 6.2% | 5.4% |
| Net Margin | -12.6% | -12.6% | -12.2% | -0.5% | -1.0% |
| Balance Sheet | |||||
| Debt/Equity | 7.77 | 7.77 | -5.29 | 4.08 | -8.89 |
| Current Ratio | 0.47 | 0.47 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-297.5M | $-297.5M | $-58.7M | $-20.5M | $36.8M |
| Returns | |||||
| ROE | -148.9% | -148.9% | 110.0% | -3.0% | 10.2% |
| Valuation | |||||
| EV/EBITDA | — | — | — | 47.04 | 31.84 |
| P/B | 20.93 | 20.93 | — | 15.94 | — |
| Growth & Yield | |||||
| Revenue Growth | 9.0% | 9.0% | 17.1% | 10.5% | — |
| EPS Growth | — | — | -2407.8% | 40.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-55.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-12.79 → n/d
Residual
-55.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.